[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053511":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":54,"id":57,"slug":10,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":76,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MGUS and Smoldering Multiple Myeloma",null,"Participants diagnosed with MGUS and smoldering multiple myeloma",[13],"Other: Blood draw for the laboratory assessment",{"label":15,"type":10,"description":16,"interventionNames":17},"Other Plasma Cell Disorders","Participants diagnosed with other plasma cell disorders",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Blood draw for the laboratory assessment","Screening blood sample collection to test for MGUS",[9,15],[24],{"name":25,"affiliation":26,"role":27},"Manisha Bhutani, MD","Atrium Health Wake Forest Baptist Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Margarita Dzhanumova","CONTACT","704-754-3768","margarita.dzhanumova@atriumhealth.org",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Atrium Health Levine Cancer","RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-80.84313,35.22709,{"lat":47,"lon":46},[50,51],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},{"name":25,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55],{"name":56,"class":6},"Atrium Health Levine Cancer Institute","100053511",false,"NCT06644625","CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study","SCREENING Inclusion Criteria:\n\n* Age 30 years or older at the time of consent\n* Either:\n\n  1. Self-identify as Black and\u002For African American OR\n  2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia\n* Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately\n* Reside in Charlotte, NC, or the surrounding area, based on self-report\n\nSCREENING Exclusion Criteria:\n\n* Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.\n\nLONGITUDINAL Inclusion Criteria:\n\n* Test positive for monoclonal gammopathy during screening portion of the study\n* Consent to the longitudinal portion of the study\n\nLONGITUDINAL Exclusion Criteria:\n\n* The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.",true,"ALL","30 Years",{"count":66,"type":67},1665,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.",[71,72,73,74,75],"Multiple Myeloma","Multiple Myeloma Progression","Monoclonal Gammopathy of Undetermined Significance (MGUS)","Smoldering Multiple Myeloma (SMM)","Plasma Cell Disorders",[77,78,79],"multiple myeloma","hematology","plasma cell disorders","2026-07-10",{"date":82,"type":83},"2026-07-13","ACTUAL",{"date":85,"type":83},"2025-03-01",{"date":87,"type":67},"2035-01",{"name":5,"class":6},1]